





To: Keystone First and Keystone First Community HealthChoices (CHC) Providers

Date: April 17, 2025

Re: Update: Formulary Changes

The following products will have new or updated quantity limits.

Members/Participants currently receiving more than the quantity limit, whom it is not medically advisable to change therapy, will require prior authorization effective **June 16, 2025.**

Formulary Limits		
Product List	Daily Quantity Limit	
Palonosetron HCl Intravenous Solution 0.25 MG/5ML	0.36 mL	
Retevmo Oral Tablet 80 MG	2 tablets	
Vijoice Oral Tablet Therapy Pack 50 MG	1 tablet	
Crexont Oral Capsule Extended Release 52.5-210 MG and 87.5-350 MG	6 capsules	
Austedo XR Oral Tablet Extended Release 24 Hour 24 MG	1 tablet	
Onyda XR Oral Suspension Extended Release 0.1 MG/ML	4 mL	

Additional prior authorization criteria may apply. Please refer to most recent drug formulary and prior authorization information available on-line at:

<u>www.keystonefirstpa.com</u> \rightarrow *Pharmacy* \rightarrow *Pharmacy Homepage* <u>www.keystonefirstchc.com</u> \rightarrow *For Providers* \rightarrow *Pharmacy services*

If you have any questions regarding this notice, please contact Pharmacy Services:

Plan Name	Telephone Number
Keystone First	1-800-588-6767
Keystone First Community HealthChoices	1-866-907-7088

Coverage by Vista Health Plan, an independent licensee of the Blue Cross and Blue Shield Association.